These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 21030905

  • 1. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial.
    Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Iversen M.
    Transplantation; 2010 Dec 27; 90(12):1581-9. PubMed ID: 21030905
    [Abstract] [Full Text] [Related]

  • 2. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 3. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
    Arora S, Gude E, Sigurdardottir V, Mortensen SA, Eiskjær H, Riise G, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Aukrust P, Solbu D, Iversen M, Gullestad L.
    J Heart Lung Transplant; 2012 Mar 15; 31(3):259-65. PubMed ID: 22333403
    [Abstract] [Full Text] [Related]

  • 4. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 15; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 5. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators.
    Transplantation; 2011 Aug 27; 92(4):410-8. PubMed ID: 21697773
    [Abstract] [Full Text] [Related]

  • 6. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec 27; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 7. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 8. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
    Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, Holdaas H, Fiane AE, Geiran OR, Andreassen AK.
    J Heart Lung Transplant; 2010 Jun 27; 29(6):641-7. PubMed ID: 20304681
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
    Ruiz JC, Sanchez-Fructuoso A, Rodrigo E, Conesa J, Cotorruelo JG, Gómez-Alamillo C, Calvo N, Barrientos A, Arias M.
    Transplant Proc; 2006 Oct 27; 38(8):2424-6. PubMed ID: 17097956
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [Abstract] [Full Text] [Related]

  • 12. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 13. Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients.
    González-Vilchez F, de Prada JA, Castrillo C, Canteli A, Llano MF, Martín-Durán R.
    J Heart Lung Transplant; 2011 May 27; 30(5):552-7. PubMed ID: 21212001
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb 27; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 15. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients.
    Sánchez Fructuoso A, Ruiz San Millán JC, Calvo N, Rodrigo E, Moreno MA, Cotorruelo J, Conesa J, Gómez-Alamillo C, Arias M, Barrientos A.
    Transplant Proc; 2007 Sep 27; 39(7):2148-50. PubMed ID: 17889120
    [Abstract] [Full Text] [Related]

  • 18. Everolimus in lung transplantation in Chile.
    Parada MT, Alba A, Sepúlveda C.
    Transplant Proc; 2010 Sep 27; 42(1):328-30. PubMed ID: 20172343
    [Abstract] [Full Text] [Related]

  • 19. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec 27; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 20. Conversion to everolimus in kidney transplant recipients with decreased renal function.
    Inza A, Balda S, Alvarez E, Zárraga S, Gaínza FJ, Lampreabe I.
    Transplant Proc; 2009 Dec 27; 41(6):2134-6. PubMed ID: 19715854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.